Cystic fibrosis–related diabetes (CFRD) is the most frequent comorbidity in people with CF. It arises from progressive pancreatic scarring, fibrosis, and fatty infiltration that gradually destroy the beta cells of the islets of Langerhans. Unlike type 1 diabetes, some endogenous insulin secretion persists for years, even decades. Unlike type 2 diabetes, insulin resistance is generally mild except during acute stress, infections, or corticosteroid use. CFRD affects approximately 20% of adolescents and 40–50% of adults with CF, with incidence rising as survival improves. The diagnosis traditionally relies on a 2-hour oral glucose tolerance test (OGTT) showing fasting glucose ≥126 mg/dL or a 2-hour value ≥200 mg/dL on two separate occasions. An HbA1c ≥6.5% can also be used for diagnosis, but HbA1c may be falsely low due to increased red blood cell turnover in CF, so OGTT remains the gold standard.

The gradual loss of beta-cell mass means that hyperglycemia first appears only after meals, but as the disease advances, fasting hyperglycemia develops. The timing and pattern of insulin deficiency differ from other diabetes types, which shapes the pharmacologic strategy. Additionally, pancreatic exocrine insufficiency, present in 85–90% of CF patients, further complicates glucose metabolism because malabsorbed nutrients are not available to regulate incretin responses and gastric emptying. Chronic inflammation, recurrent infections, altered gut microbiota, and the high-calorie nutritional needs necessary to maintain weight all affect glucose homeostasis. Understanding these underlying mechanisms is essential before selecting glucose-lowering medications.

Pharmacologic Landscape for CFRD

The primary goal of drug therapy in CFRD is to achieve near-normal glycemia without causing excessive weight gain, worsening malnutrition, or increasing hypoglycemia risk. Insulin remains the cornerstone, but oral agents and other adjuncts may be considered in selected patients, provided their limitations are respected.

Insulin Therapy

Insulin directly replaces the deficient endogenous secretion and can be titrated to match the variable carbohydrate intake typical in CF. Multiple insulin formulations are available, each with distinct pharmacodynamics that must be understood in the context of CF physiology.

  • Rapid-acting analogs (lispro, aspart, glulisine) have an onset of 10–15 minutes, peak at 30–90 minutes, and last 3–5 hours. They are preferred for mealtime coverage because they can be injected immediately before or after eating, accommodating erratic appetite. Their rapid clearance reduces late hypoglycemia.
  • Short-acting regular insulin works within 30 minutes, peaks at 2–3 hours, and lasts 5–8 hours. Its slower absorption often leads to mismatched postprandial coverage and higher late hypoglycemia risk, making it a less desirable choice in CFRD compared to rapid analogs.
  • Intermediate-acting NPH has peak activity at 4–8 hours and a duration of 12–18 hours. It is sometimes used in twice-daily regimens, but variable absorption due to altered subcutaneous tissue in CF makes it less predictable. Many clinicians avoid NPH except in very stable patients.
  • Long-acting analogs (glargine U-100/U-300, detemir, degludec) provide a relatively flat basal insulin profile. Degludec’s ultra-long duration of action (over 42 hours) may reduce injection burden to once daily, but its prolonged activity can mask hypoglycemia if dosing adjustments are needed rapidly.

Dosing in CFRD must consider several factors: increased insulin sensitivity during stable health (total daily dose often starts at 0.3–0.5 units/kg/day) and significant insulin resistance during acute exacerbations, corticosteroid use, or systemic infections. Many clinicians adopt a basal-bolus regimen with rapid-acting insulin at meals plus one or two daily basal injections. Insulin pump therapy (continuous subcutaneous insulin infusion) offers additional flexibility, especially for patients with gastroparesis, night-shift work, or highly variable meal schedules. Continuous glucose monitoring (CGM) has become standard to fine-tune insulin dosing and detect postprandial excursions and asymptomatic hypoglycemia. A 2022 review in Pediatric Diabetes highlights the benefits of CGM and pump therapy in CFRD for reducing glycemic variability.

Oral Hypoglycemic Agents

Oral agents are not first-line for CFRD, but they may have a place in patients with mild glucose intolerance, preserved beta-cell function, and a low risk of adverse effects. The evidence base is limited, and each class brings unique concerns in the CF population.

  • Sulfonylureas (glipizide, glimepiride) stimulate insulin secretion by closing ATP-sensitive potassium channels on beta cells. They can cause hypoglycemia, weight gain, and reduced efficacy as beta-cell function declines. Erratic gastrointestinal absorption and hepatic impairment in CF make dose titration difficult. However, they may benefit patients with very early CFRD who still have substantial endogenous insulin reserve, especially if they cannot tolerate multiple daily injections.
  • Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity without stimulating insulin release. Its greatest risk is lactic acidosis, a concern in CF patients who often have some degree of hepatic steatosis, renal impairment (eGFR <45 mL/min is a contraindication), or chronic hypoxemia. Metformin also frequently causes nausea, diarrhea, and abdominal discomfort, which can worsen CF-related malnutrition. Some clinicians consider metformin only for CFRD patients with concurrent obesity or metabolic syndrome, after thorough hepatic and renal assessment and with close GI tolerance monitoring.
  • DPP-4 inhibitors (sitagliptin, linagliptin) potentiate incretin hormones, leading to glucose-dependent insulin secretion and reduced glucagon. They have a low hypoglycemia risk and are weight neutral. Small observational studies and one small randomized controlled trial suggest they may be safe and possibly effective in CFRD, but large randomized trials are absent. They could be considered second-line for patients who cannot use insulin but have adequate beta-cell function.
  • SGLT2 inhibitors (empagliflozin, dapagliflozin) lower glucose by increasing urinary glucose excretion. They carry risks of volume depletion, euglycemic diabetic ketoacidosis (DKA), and urinary tract infections. In CF, where DKA risk is elevated during infections and baseline volume status is often tenuous, these agents are generally contraindicated outside research settings. Some trials are exploring lower doses but no clinical recommendation exists.
  • GLP-1 receptor agonists (liraglutide, semaglutide) stimulate insulin secretion and slow gastric emptying. They frequently cause nausea and vomiting, and they have been associated with pancreatitis—a particularly hazardous scenario in CF patients already at risk for pancreatic inflammation. Use is not recommended.

Clinicians prescribing oral agents for CFRD must start with low doses, titrate slowly, and monitor closely for adverse effects and loss of efficacy as beta-cell function wanes over time.

Adjunct Medications

Inhaled insulin (Afrezza) has been studied in small CF cohorts because it produces a rapid spike in insulin levels post-inhalation. However, it can induce cough and bronchospasm in patients with compromised lung function, limiting its use. Pramlintide, an amylin analog that delays gastric emptying and suppresses glucagon, adds nausea and hypoglycemia risk, making it unattractive in undernourished patients. In practice, insulin remains the sole therapy for the vast majority of CFRD patients, and adjunct medications are rarely employed.

Pharmacokinetic and Pharmacodynamic Considerations in CF

CF profoundly alters drug absorption, distribution, metabolism, and excretion. These changes must be accounted for when prescribing diabetes medications.

Absorption

Pancreatic insufficiency causes fat malabsorption, which reduces the bioavailability of lipophilic drugs such as sulfonylureas and some insulin formulations. Rapid gastrointestinal transit and intestinal inflammation further limit drug exposure. For oral agents, timing with pancreatic enzyme replacement therapy may improve absorption. Insulin absorption from subcutaneous tissue can be erratic because of altered blood flow, edema, or lipodystrophy at injection sites. Inhaled insulin faces reduced lung surface area, thickened mucus, and impaired alveolar absorption due to chronic infection and inflammation. To minimize variability, many clinicians prefer rapid-acting insulin analogs and avoid long-acting preparations that rely on depot formation, instead using insulin pumps or twice-daily dosing of basal analogs.

Metabolism and Clearance

Hepatic steatosis, cirrhosis, and portal hypertension are common in CF, impairing cytochrome P450 enzyme activity. Sulfonylureas metabolized by CYP2C9 (e.g., glimepiride, glipizide) may accumulate, increasing hypoglycemia risk. Insulin is cleared by both liver and kidneys. CF-related kidney disease (nephrocalcinosis, amyloidosis) can prolong insulin action and heighten hypoglycemia risk. Renal function should be monitored at least annually; metformin and SGLT2 inhibitors require dose adjustments or avoidance when eGFR drops below 45 mL/min. DPP-4 inhibitors such as sitagliptin and saxagliptin are excreted renally, so doses must be reduced in renal impairment. Linagliptin is primarily hepatobiliary and does not require dose adjustment, making it potentially safer in CF patients with compromised kidneys.

Drug Interactions

CF patients often take multiple medications that interact with diabetes drugs. Important interactions include:

  • CFTR modulators (ivacaftor, tezacaftor, elexacaftor) affect drug metabolizing enzymes. Ivacaftor is a moderate CYP3A4 inducer, potentially reducing exposure to sulfonylureas that are CYP3A4 substrates. Elexacaftor inhibits several CYP enzymes, which may raise levels of drugs like sitagliptin. These interactions can require dose adjustments. Recent evidence also suggests that CFTR modulators may improve insulin secretion, but that is separate from pharmacokinetic interactions.
  • Macrolide antibiotics (azithromycin) inhibit CYP3A4 and can increase sulfonylurea concentrations, raising hypoglycemia risk. Fluoroquinolones (ciprofloxacin, levofloxacin) can cause dysglycemia, both hypoglycemia and hyperglycemia, complicating insulin dose management.
  • Corticosteroids, used for airway inflammation or allergic bronchopulmonary aspergillosis, induce insulin resistance and raise blood glucose. Insulin requirements may double during high-dose prednisone courses. Close glucose monitoring and proactive insulin dose adjustments are mandatory. Some centers implement scheduled insulin dose increases at the start of steroid therapy.
  • Pancreatic enzymes do not directly interact, but improving fat digestion can stabilize postprandial glucose patterns. Ensuring proper enzyme supplementation helps reduce glycemic variability.

Evidence-Based Treatment Guidelines for CFRD

The Cystic Fibrosis Foundation and the American Diabetes Association have published consensus guidelines that provide a framework for pharmacologic management. Key recommendations include:

  • Insulin is the primary therapy once CFRD is confirmed. A basal-bolus regimen (rapid-acting analogs at meals plus a long-acting basal insulin) or insulin pump is the preferred approach.
  • Oral agents are not first-line. Metformin may be considered for patients with mild fasting hyperglycemia, preserved beta-cell function, and no significant liver or kidney disease, but only with vigilant monitoring. Sulfonylureas and DPP-4 inhibitors have a limited role.
  • SGLT2 inhibitors and GLP-1 agonists are not recommended outside clinical trials because of safety concerns.
  • Self-monitoring of blood glucose, including both pre-meal and postprandial values, is essential. CGM is strongly encouraged for its ability to capture glycemic patterns and reduce hypoglycemia unawareness.
  • During acute illness, hospitalization, or surgery, insulin doses often need to be escalated, sometimes with intravenous insulin infusions to maintain target glucose levels.
  • Nutritional management should be integrated: high-calorie diets, consistent carbohydrate intake (usually from 30–60 g per meal depending on individual needs), and proper timing of pancreatic enzymes support glycemic control.

For further details, the Cystic Fibrosis Foundation’s CFRD Clinical Care Guidelines provide comprehensive algorithms. The American Diabetes Association Standards of Care includes a dedicated CFRD section. A detailed review of insulin pharmacology in CF can be found in this article in Diabetes Care. Emerging evidence on continuous glucose monitoring and insulin pump therapy is discussed in a 2022 review in Pediatric Diabetes.

Special Situations and Future Directions

Managing diabetes during pregnancy in CF requires particular attention. Insulin is the only recommended agent during pregnancy because oral agents lack safety data and may cross the placenta. Glucose targets are stricter (fasting <95 mg/dL, 1-hour postprandial <140 mg/dL), and insulin needs often increase as pregnancy progresses. After delivery, doses must be rapidly reduced. Another challenging scenario is the use of high-dose corticosteroids for lung disease exacerbations; insulin may be initiated or escalated even before glucose rises, based on the expected insulin-resistance effect. Some centers use insulin sliding scales during acute illness, but basal-bolus protocols are more effective and associated with better outcomes.

Respiratory exacerbations themselves often cause significant hyperglycemia due to stress hormones and pro-inflammatory cytokines. During such episodes, insulin doses may need to be increased by 30–50% even without corticosteroids. Post-lung transplant CFRD management is another area requiring careful attention: immunosuppressive regimens (tacrolimus, corticosteroids) increase insulin resistance, and infection prophylaxis may further interact. In this setting, basal-bolus insulin remains the mainstay, but oral agents are sometimes considered under expert guidance. A 2020 review in Diabetes Care discusses these peri-transplant challenges.

Research is exploring whether CFTR modulators, by restoring some pancreatic function, can delay or even reverse CFRD in some patients. Early data suggest that elexacaftor/tezacaftor/ivacaftor may improve insulin secretion in a subset of individuals with residual beta-cell function. If confirmed, this could shift the pharmacologic paradigm from insulin replacement to strategies that protect and preserve beta-cell mass. Meanwhile, advances in closed-loop insulin delivery systems (artificial pancreas) are being tested in CFRD, promising to automate glucose management and improve quality of life. Recent pilot studies show that hybrid closed-loop systems can improve time-in-range and reduce hypoglycemia in adults with CFRD, suggesting a future where technology plays a central role.

Another area of active investigation is the role of incretin hormones in CFRD. Glucagon-like peptide-1 (GLP-1) secretion appears to be impaired in CF, but the use of GLP-1 receptor agonists is limited by gastrointestinal side effects. However, dual agonists (e.g., tirzepatide) or agents that combine GIP and GLP-1 actions may someday provide benefit if tolerability improves. For now, these remain experimental in CF.

Conclusion

The pharmacologic management of diabetes in cystic fibrosis patients is shaped by a unique disease biology, altered drug handling, and the need for flexible dosing to accommodate variable nutritional status and intercurrent illnesses. Insulin remains the safest and most effective therapy, with rapid-acting analogs and long-acting basal analogs or pump therapy forming the backbone of treatment. Oral agents have a limited, carefully selected role, primarily in patients with early disease and preserved beta-cell function. Clinicians must be vigilant about drug interactions, hepatic and renal function, the impact of CFTR modulators on drug metabolism, and the ever-present risk of hypoglycemia and malnutrition. With the integration of CGM, insulin pump technology, and emerging therapies, the outlook for achieving excellent glycemic control in CFRD continues to improve, supporting better nutritional status, lung function, and long-term survival.